


MEDICAL INTERNATIONAL TECHNOLOGY INC (Filer) CIK: 0001112372[Print Document](#) [View Excel Document](#)

Cover
Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
Notes Tables
Notes Details
 All Reports

Document and Entity Information	9 Months Ended	
	Jun. 30, 2012	Aug. 14, 2012
Document and Entity Information [Abstract]		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	0001112372	
Amendment Flag	false	
Current Fiscal Year End Date	--09-30	
Document Period End Date	Jun. 30, 2012	
Entity Filer Category	Smaller Reporting Company	
Document Fiscal Period Focus	Q3	
Document Type	10-Q	
Document Fiscal Year Focus	2012	
Entity Common Stock, Shares Outstanding		83,804,627

Consolidated Balance Sheet (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Current Assets		
Cash and cash equivalents		\$ 10,889
Accounts receivable	51,689	48,349
Inventories	276,825	322,906
Prepaid expenses	7,440	18,820
Total Current Assets	335,954	400,964
Long Term Investment		
Investment in MIT China Joint Venture	57,284	242,056
Property and Equipment		
Tooling and machinery	688,994	678,918
Furniture and office equipment	139,747	147,950
Leasehold improvements	28,751	30,438
Total property and equipment	857,492	857,306
Less accumulated depreciation	(562,217)	(502,782)
Total property and equipment, net	295,275	354,524
Other Assets		
Patents (net of accumulated amortization of \$9,412 and \$16,097)	31,948	23,781
Total assets	720,461	1,021,325
Current Liabilities		
Bank overdraft	402	
Bank line	24,533	31,167
Deferred income	1,083,834	1,083,317
Accounts payable and accrued expenses	246,477	209,310
Amounts due to related parties		152,723
Total current liabilities	1,355,246	1,476,517
Long-Term Debts	205,200	177,247
Total Liabilities	1,560,446	1,653,764
Stockholders' Equity (Deficit)		
Preferred stock, \$.0001 par value; 3,000,000 shares authorized; None issued and outstanding as of December 31, 2007		
Common stock, \$.0001 par value; 100,000,000 shares authorized; 83,804,627 and 83,804,627 shares issued and Outstanding, respectively	7,979	7,909
Additional paid-in capital	12,867,476	12,804,206
Deficit	(13,316,317)	(13,062,171)
Other comprehensive income (loss)	(399,123)	(382,381)
Total Stockholders' Equity (Deficit)	(839,985)	(632,439)
Total Liabilities and Stockholders' Equity (Deficit)	\$ 720,461	\$ 1,021,325

Consolidated Balance Sheet (Parenthetical) (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Statement Of Financial Position [Abstract]		
Accumulated amortization (Patents)	\$ 9,412	\$ 16,097
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	83,804,627	83,804,627
Common stock, shares outstanding	83,804,627	83,804,627

Consolidated Statements of Operations (Unaudited) (USD \$)	3 Months Ended		9 Months Ended	
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Income Statement [Abstract]				
Sales	\$ 401,157	\$ 89,248	\$ 828,644	\$ 290,503
Cost of sales	(95,989)	(33,909)	(195,486)	(99,915)
Gross profit (loss)	305,168	55,339	633,158	190,588
Selling, general, and administrative expenses	(215,403)	(214,597)	(664,266)	(412,243)
Operating Expenses	(215,403)	(214,597)	(664,266)	(412,243)
Gain (loss) from operations	89,765	(159,258)	(31,108)	(221,655)
Other Income (Expense)				
Equity earnings (loss) on MIT China Joint Venture	(80,166)	(60,968)	(184,773)	(81,802)
Interest income/loss	240		824	
Interest expense	(4,065)	(24,687)	(39,089)	(31,867)
Total other income (expense)	(83,991)	(1,685)	(223,038)	(113,669)
Net income (loss)	\$ 5,774	\$ (244,873)	\$ (254,146)	\$ (335,324)
Basic income (loss) per share	\$ (0.0001)	\$ (0.0003)	\$ (0.003)	\$ (0.004)
Basic weighted average shares outstanding	83,804,627	71,478,627	83,804,627	71,478,627

Consolidated Statements of Cash Flows (Unaudited) (USD \$)	9 Months Ended	
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:		
Net loss	\$ (254,146)	\$ (335,324)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Equity loss from MIT China Joint Venture	184,733	81,802
Depreciation and amortization expense	94,517	27,232
Common stock issued for services		31,000
Changes in:		
Accounts receivable	(3,340)	(3,586)
Inventories	46,082	(135,994)
Prepaid expenses	11,380	(19,013)
Accounts payable and accrued liabilities	61,700	(202,266)
Deferred income	518	112,092
Net cash used by operating activities	<u>141,484</u>	<u>(444,057)</u>
Cash flows from investing activities:		
Acquisition of patents	(16,692)	(10,579)
Investment in MIT China joint venture		
Tooling and machinery	(47,718)	(97,625)
Net cash used by investing activities	<u>(64,410)</u>	<u>(108,204)</u>
Cash flows from financing activities:		
Bank line	(31,167)	
Bank overdraft	402	
Bank loans	27,953	123,533
Proceeds from issuance of stock, net	63,340	491,581
Decrease in amounts due to related parties	(152,723)	(26,191)
Issuance of notes payable		
Repayment on notes payable		
Net cash provided from financing activities	<u>(92,195)</u>	<u>588,923</u>
Effect of exchange rates	4,232	(11,185)
Increase (decrease) in cash	<u>(10,889)</u>	<u>25,477</u>
Cash, beginning of period	10,889	26,716
Cash, end of period		52,193
Supplemental disclosure of cash flow information:		
Cash paid for interest	39,089	31,867
Cash paid for federal income taxes		
Supplemental disclosure of non-cash transactions		
Common stock issued for debt reductions		

Consolidated Statements of Comprehensive Loss (Unaudited) (USD \$)	9 Months Ended	
	Jun. 30, 2012	Jun. 30, 2011
Statement Of Income and Comprehensive Income		
[Abstract]		
Net loss	\$ (254,146)	\$ (335,324)
Other comprehensive income (loss)		
Foreign currency translation adjustment	(16,742)	(15,365)
Net comprehensive income (loss)	<u>\$ (270,888)</u>	<u>\$ (350,689)</u>

Consolidated Statement of Stockholders' (Deficit) (Unaudited) (USD \$)	Total	Common Stock	Additional Paid- In Capital	Additional Paid In Deficit
Beginning Balance at Sep. 30, 2011		\$ 7,909	\$ 12,804,206	\$ (13,062,171)
Beginning Balance, Shares at Sep. 30, 2011		79,090,627	0	0
Shares issued for debts				
Shares issued for services				
Shares issued for additional capital		20	17,980	
Shares issued for additional capital, Shares		180,000		
Net loss				(235,153)
Ending Balance at Dec. 31, 2011		7,929	12,822,186	(13,297,324)
Ending Balance, Shares at Dec. 31, 2011		79,270,627		
Shares issued for debts				
Shares issued for services		50	45,290	
Shares issued for services, Shares		4,534,000		
Shares issued for additional capital				
Shares issued for additional capital, Shares				
Net loss				(24,767)
Ending Balance at Mar. 31, 2012		7,979	12,867,476	(13,322,091)
Ending Balance, Shares at Mar. 31, 2012		83,804,627		
Shares issued for debts				
Shares issued for services				
Shares issued for services, Shares				
Shares issued for additional capital				
Shares issued for additional capital, Shares				
Net loss	5,774			(5,774)
Ending Balance at Jun. 30, 2012	\$ (839,985)	\$ 7,979,000	\$ 12,867,476	\$ (13,316,317)
Ending Balance, Shares at Jun. 30, 2012		83,804,627		

Basis of Presentation	9 Months Ended Jun. 30, 2012
Accounting Policies [Abstract] Basis of Presentation	Note 1 – Basis of Presentation
	Interim Financial Statements
	<p>The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. (“MIT” or the “Company”) and its subsidiary (collectively referred to as the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2011.</p>
	<p>In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months period ended June 30, 2012 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2012. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of</p>

assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Inventories	9 Months Ended Jun. 30, 2012	
Inventory Disclosure [Abstract] Inventories		
Note 2 – Inventories		
Inventories at June 30, 2012 and September 30, 2011 consist of the following:		
	June 30, 2012	September 30, 2011
Raw materials	\$216,907	\$ 208,892
Work in process	57,780	102,259
Finished goods	2,138	11,755
Total	<u>\$276,825</u>	<u>\$ 322,906</u>

Property and Equipment	9 Months Ended Jun. 30, 2012
Property, Plant and Equipment [Abstract] Property and Equipment	<p data-bbox="917 346 1177 409">Note 3 – Property and Equipment</p> <p data-bbox="917 430 1291 819">The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the nine months ended June 30, 2012 and 2011 was \$87,311 and \$22,144, respectively</p>

Intangible Assets	9 Months Ended Jun. 30, 2012								
<p>Goodwill and Intangible Assets Disclosure [Abstract]</p> <p>Intangible Assets</p>									
<p>Note 4 – Intangible Assets</p>									
<p>As of June 30, 2012, the Company has net patents and certain technologies aggregating \$31,948. Amortization expense for the years ended June 30, 2012 and 2011 were \$16,096 and \$5,761, respectively. During the nine months ended June 30, 2012, the Company capitalized patent costs on its needle-free injector of \$16,692. Following is a detail of patents as of June 30, 2012:</p>									
<table border="0"> <thead> <tr> <th style="text-align: center;">Gross Intangible Assets</th> <th style="text-align: center;">Accumulated Amortization</th> <th style="text-align: center;">Net Intangible Assets</th> <th style="text-align: center;">Weighted Average Life (Years)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">\$ 48,045</td> <td style="text-align: center;">\$ 16,097</td> <td style="text-align: center;">\$ 31,948</td> <td style="text-align: center;">7.5 through 15</td> </tr> </tbody> </table>	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)	\$ 48,045	\$ 16,097	\$ 31,948	7.5 through 15	
Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)						
\$ 48,045	\$ 16,097	\$ 31,948	7.5 through 15						

Joint Venture Agreement

9 Months Ended

Jun. 30, 2012

Equity Method Investments and Joint Ventures
[Abstract]

Joint Venture Agreement

Note 5 – Joint Venture Agreement

On May 6, 2009, the Company entered into a certain joint venture agreement (the “Joint Venture Agreement”) with Jiangsu Hualan Biotechnology Ltd. (China) (“Jiangsu Hualan”). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China” or the “Joint Venture”), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company’s needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of \$714,000, and owns 51% of the registered capital.

Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party’s investment in the registered capital.

During the period from May 6, 2009 to September 30, 2009, the Joint Venture had not commenced operations. The Joint Venture

commenced operations during the Company's 1st quarter of fiscal 2010.

The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of September 30, 2011, the Company's recorded investment in the MIT China was \$242,056. During the nine months ended June 30, 2012, the Company recorded an equity loss from its investment in MIT China of \$184,773.

Bank Line	9 Months Ended Jun. 30, 2012
Bank Line [Abstract] Bank Line	Note 6 – Bank Line
	The Company has an equipment line of credit up to a maximum of \$350,000. The line is secured by account receivables, inventories, equipment and all other assets of the Company. At June 30, 2012, the Company had no amounts outstanding under the agreement.

Related Party Transactions	9 Months Ended Jun. 30, 2012	
Related Party Transactions [Abstract]		
Related Party Transactions		
Note 7 – Related Party Transactions		
Related party balances consist of the following at June 30, 2012 and September 30, 2011:		
	June 30, 2012	September 30, 2011
Payable to 2849-674 Canada Inc	\$ -	\$ 72,723
Payable to 9211-0766 Quebec Inc	-	80,000
	<u>\$ -</u>	<u>\$ 178,767</u>
The Company has borrowed from shareholders and corporations owned by shareholders. These loans are bearing interest at 8%, and are due during fiscal 2012.		

Stockholders' Equity (Deficit)	9 Months Ended Jun. 30, 2012
Equity [Abstract] Stockholders' Equity (Deficit)	Note 8 – Stockholders' Equity (Deficit)
	<u>Issuance of Common Stock</u>
	From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.
	For the quarter ended June 30, 2012, there were no common stock issuances.
	<u>Preferred Stock</u>
	As of June 30, 2012, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.
	<u>Outstanding Options</u>
	As of June 30, 2012 and 2011, there are no options outstanding to purchase shares of the Company's common stock.
	<u>Outstanding Warrants</u>
	During the period ended June 30, 2011, the Company issued warrants to purchase an aggregate of 2,815,000 common shares at an exercise price of \$0.15 per share and 333,332 common shares at an exercise price of \$0.20 per share. The warrants were issued in connection with private placements completed during 2011. The warrants vested immediately and have terms of one to two years that expire between March 28, 2012 and February 4, 2013. The Company estimated the fair value of the warrants using the Black-Scholes method with assumptions including: (1) term of 1 year to two years; (2) a computed volatility rate of 205%; (3) a

discount rate of 0.45%; and (4) zero dividends. The fair value of the warrants was estimated to be \$218,991.

Operating Leases	9 Months Ended Jun. 30, 2012
Leases [Abstract] Operating Leases	
	Note 9 –Operating Leases
	The Company leases its office and warehouse space under an operating lease that expires on December 31, 2014 that calls for a monthly rent of \$4,414. Rent expense for the nine months ended June 30, 2012 was approximately \$38,500.
	Future minimum lease commitments pertaining to the lease expire as follow:
	<u>Year ended</u>
	September 30, 2012 52,549
	September 30, 2013 52,964
	September 30, 2014 52,964
	Thereafter <u>13,241</u>
	<u>\$171,718</u>

Deferred Income	9 Months Ended Jun. 30, 2012	
Deferred Income [Abstract] Deferred Income		
Note 10– Deferred Income		
Deferred income consists of the following at June 30, 2012 and September 30, 2011:		
	June 30, 2012	September 30, 2011
Deposits from customers and distributors	\$ 11,335	\$ 10,817
Non-refundable Distribution Rights Deposit	<u>1,072,500</u>	<u>1,072,500</u>
Total	<u>\$1,083,835</u>	<u>\$ 1,078,009</u>
<p>On November 1, 2007, the Company received a deposit of \$1,300,000 for the worldwide rights to market and sells while maintaining our right to sell all Medical International Technology Inc.'s Needle-Free Jet-Injectors for the human and animal markets. This deposit was part of an agreement under negotiation, which was finalized in January 2009. Upon finalization, the Company began recognizing the deposit into income over the contractual life of the agreement. During the year ended September 30, 2010, the Company recognized \$130,000 into income under this agreement. During 2011, the Company was notified of potential litigation related to this contract. Accordingly, due to the uncertainty in a final resolution, the Company ceased recognizing income related to this contract during 2011. Upon a final resolution of the dispute, the Company will begin amortizing the deposit into income over the remaining contractual life of the agreement.</p>		

Notes Payable	9 Months Ended	
Debt Disclosure [Abstract]	Jun. 30, 2012	
Notes Payable	June 30, 2012	September 30, 2011
Note 11 –Notes Payable		
Long-term debt consists of the following at June 30, 2012 and September 30, 2011:		
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$126,144	\$ 82,227
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	<u>79,056</u>	<u>95,020</u>
Long-term debt	<u>\$205,200</u>	<u>\$ 177,247</u>
Future scheduled principal payments under note agreements are as follows:		
June 30, 2013		28,957

June 30, 2014	51,442
June 30, 2015	51,442
June 30, 2016	51,442
June 30, 2017	21,917
	<u><u>\$205,200</u></u>

Contingencies	9 Months Ended Jun. 30, 2012
Commitments and Contingencies Disclosure [Abstract] Contingencies	<p data-bbox="922 380 1192 407">Note 12 – Contingencies</p> <p data-bbox="922 438 1127 466">Legal Proceedings</p> <p data-bbox="922 497 1289 730">From time to time, the Company is named in legal actions in the normal course of business. In the opinion of management, the outcome of these matters, if any, will not have a material impact on the financial condition or results of operations of the Company.</p> <p data-bbox="922 749 1289 806">Investment in MIT China Joint Venture</p> <p data-bbox="922 827 1289 1528">The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, “Investment — Equity Method and Joint Venture” (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock.” Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of June 30, 2012, the Company’s recorded investment in the MIT China was \$57,284. During the nine months ended June 30, 2012, the Company recorded an equity loss from its investment in MIT China of \$184,773.</p>

Contingencies (Policies)	9 Months Ended Jun. 30, 2012
Commitments and Contingencies Disclosure [Abstract]	
Investment - Equity Method and Joint Venture	<p>The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of June 30, 2012, the Company's recorded investment in the MIT China was \$57,284. During the nine months ended June 30, 2012, the Company recorded an equity loss from its investment in MIT China of \$184,773.</p>

Inventories (Tables)	9 Months Ended	
	Jun. 30, 2012	
Inventory Disclosure [Abstract]		
Component of Inventories		
	June 30,	September 30,
	2012	2011
Raw materials	\$216,907	\$ 208,892
Work in process	57,780	102,259
Finished goods	2,138	11,755
Total	<u>\$276,825</u>	<u>\$ 322,906</u>

Intangible Assets (Tables)		9 Months Ended Jun. 30, 2012		
Goodwill and Intangible Assets Disclosure [Abstract]				
Details of patent				
	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)
	<u> </u>	<u> </u>	<u> </u>	7.5 through
Patents \$	48,045 \$	16,097 \$	31,948	15

Related Party Transactions (Tables)	9 Months Ended Jun. 30, 2012	
Related Party Transactions [Abstract]		
Component of related party balances		
	June 30, 2012	September 30, 2011
Payable to 2849- 674 Canada Inc	\$ -	\$ 72,723
Payable to 9211- 0766 Quebec Inc	-	80,000
	\$ -	\$ 178,767
	\$ -	\$ 178,767

Operating Leases (Tables)		9 Months Ended
Leases [Abstract]		Jun. 30, 2012
Future minimum lease commitments		
	<u>Year ended</u>	
	September 30, 2012	52,549
	September 30, 2013	52,964
	September 30, 2014	52,964
	Thereafter	<u>13,241</u>
		<u>\$171,718</u>

Deferred Income (Tables)	9 Months Ended	
Deferred Income [Abstract]	Jun. 30, 2012	
Deferred income disclosure	June 30, 2012	September 30, 2011
Deposits from customers and distributors	\$ 11,335	\$ 10,817
Non- refundable Distribution Rights Deposit	<u>1,072,500</u>	<u>1,072,500</u>
Total	<u>\$1,083,835</u>	<u>\$ 1,078,009</u>

Notes Payable (Tables)	9 Months Ended Jun. 30, 2012	
Debt Disclosure [Abstract] Schedule of long-term debt	June 30, 2012	September 30, 2011
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$126,144	\$ 82,227
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	<u>79,056</u>	<u>95,020</u>
Long-term debt	<u>\$205,200</u>	<u>\$ 177,247</u>
Future scheduled principal payments of long-term debt		
June 30, 2013		28,957
June 30, 2014		51,442
June 30, 2015		51,442
June 30, 2016		51,442
June 30, 2017		21,917
		<u>\$205,200</u>



Inventories (Details) (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Component of Inventories		
Raw materials	\$ 216,907	\$ 208,892
Work in process	57,780	102,259
Finished goods	2,138	11,755
Total	<u>\$ 276,825</u>	<u>\$ 322,906</u>

Property and Equipment (Details) (USD \$)	9 Months Ended	
	Jun. 30, 2012	Jun. 30, 2011
Property and Equipment (Textual)		
Depreciation expense	\$ 87,311	\$ 22,144
Minimum [Member]		
Property and Equipment (Textual)		
Estimated useful lives of property and equipment	5 months	
Maximum [Member]		
Property and Equipment (Textual)		
Estimated useful lives of property and equipment	7 months	

Intangible Assets (Details) (USD \$)	Jun. 30, 2012	Sep. 30, 2011	Jun. 30, 2012 Patents [Member]	9 Months Ended	
				Jun. 30, 2012 Patents [Member] Minimum [Member]	Jun. 30, 2012 Patents [Member] Maximum [Member]
Detail of patents					
Gross Intangible Assets			\$ 48,045		
Accumulated amortization (Patents)	9,412	16,097	16,097		
Net Intangible Assets	<u>\$ 31,948</u>	<u>\$ 23,781</u>	<u>\$ 31,948</u>		
Weighted Average Life (Years)				7 years 6 months	15 years

Intangible Assets (Details Textual) (USD \$)	9 Months Ended		
	Jun. 30, 2012	Jun. 30, 2011	Sep. 30, 2011
Intangible Assets (Textual)			
Net Intangible Assets	\$ 31,948		\$ 23,781
Amortization expenses	16,096	5,761	
Capitalized patent costs on needle-free injector	\$ 16,692	\$ 10,579	

Joint Venture Agreement (Details) (USD \$)	1 Months Ended May 31, 2009	9 Months Ended Jun. 30, 2012	Sep. 30, 2011	May 06, 2009
Joint Venture Agreement (Textual)				
Ownership Percentage				49.00%
Cash invested in joint venture		\$ 57,284	\$ 242,056	\$ 426,678
Number of members appointed under joint venture agreemnet	1			
Investment to be made by Joint Venture				2,000,000
Registered capital				1,400,000
Value of license rights				280,000
License cost	426,678			
Investment in joint venture		242,056		
Equity loss from its investment		184,773		
Jiangsu Hualan [Member]				
Joint Venture Agreement (Textual)				
Ownership Percentage				51.00%
Cash invested in joint venture				\$ 714,000
Number of members appointed under joint venture agreemnet	2			

Bank Line (Details) (USD \$)	Jun. 30, 2012
Bank Line (Textual)	
Maximum equipment line of credit	\$ 350,000
Amount Outstanding	

Related Party Transactions (Details) (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Related party balances		
Related party balances		\$ 178,767
Payable to 2849-674 Canada Inc [Member]		
Related party balances		
Related party balances		72,723
Payable to 9211-0766 Quebec Inc [Member]		
Related party balances		
Related party balances		\$ 80,000

Related Party Transactions (Details Textual)	9 Months Ended Jun. 30, 2012
Related Party Transaction (Textual) Interest rate on loan	8.00%

Stockholders' Equity (Deficit) (Details) (USD \$)	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Sep. 30, 2011
Stockholders Equity (Textual)			
Stock issued during period, value, new issue			
Preferred stock, shares outstanding			
Options outstanding			
Warrants vesting term, minimum		1 year	
Warrants vesting term, maximum		2 years	
Estimated fair value of warrant	\$ 218,991		\$ 218,991
Warrant [Member]			
Stockholders Equity (Textual)			
Fair Value Assumptions, Expected Volatility Rate			205.00%
Discount rate			0.45%
Fair Value Assumptions, Expected Dividend Payments			\$ 0
Warrant [Member] Maximum [Member]			
Stockholders Equity (Textual)			
Fair Value Assumptions, Expected Term		2 years	
Warrant [Member] Minimum [Member]			
Stockholders Equity (Textual)			
Fair Value Assumptions, Expected Term		1 year	
Exercise Price 1 [Member]			
Stockholders Equity (Textual)			
Number of common shares to be purchase from Warrants issued			2,815,000
Exercise price of warrants			\$ 0.15
Exercise Price 2 [Member]			
Stockholders Equity (Textual)			
Number of common shares to be purchase from Warrants issued			333,332
Exercise price of warrants			\$ 0.20

Operating Leases (Details) (USD \$)		Jun. 30, 2012
Future minimum lease commitments		
September 30, 2012		\$ 52,549
September 30, 2013		52,964
September 30, 2014		52,964
Thereafter		13,241
Operating Leases, Future Minimum Payments Due		<u>\$ 171,718</u>

Operating Leases (Details Textual) (USD \$)		9 Months Ended
		Jun. 30, 2012
Operating leases (Textual)		
Expiry date of operating lease	Dec. 31, 2014	
Monthly rent for office and warehouse space		\$ 4,414
Rent expense		\$ 38,500

Deferred Income (Details) (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Deferred income disclosure		
Deposits from customers and distributors	\$ 11,335	\$ 10,817
Non-refundable Distribution Rights Deposit	1,072,500	1,072,500
Total	<u>\$ 1,083,834</u>	<u>\$ 1,083,317</u>

Deferred Income (Details Textual) (USD \$)	12 Months Ended	
	Sep. 30, 2010	Nov. 01, 2007
Deferred Income (Textual)		
Deposit received for the worldwide rights to market and sell rights		\$ 1,300,000
Deferred revenue recognized	\$ 130,000	

Notes Payable (Details) (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Long-term debt		
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$ 126,144	\$ 82,227
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	79,056	95,020
Long-term debt	<u>\$ 205,200</u>	<u>\$ 177,247</u>

Notes Payable (Details 1) (USD \$)	Jun. 30, 2012	Sep. 30, 2011
Future scheduled principal payments of long-term debt		
June 30, 2013	\$ 28,957	
June 30, 2014	51,442	
June 30, 2015	51,442	
June 30, 2016	51,442	
June 30, 2017	21,917	
Long-term debt	<u>\$ 205,200</u>	<u>\$ 177,247</u>

Notes Payable (Details Textual) (USD \$)		9 Months Ended
		Jun. 30, 2012
Notes payable to bank		
Notes Payable (Textual)		
Interest rate in addition to prime rate		3.00%
Number of consecutive installments for repayment of long-term debt		60
Installment amount for repayment of long-term debt		\$ 2,413.12
Debt issuance date	Jan. 20, 2012	
Debt maturity date	Jan. 20, 2016	
Canada economic development		
Notes Payable (Textual)		
Interest rate in addition to prime rate		
Number of consecutive installments for repayment of long-term debt		16
Due date of first installment	Twelve (12) month after the project completion date.	

Contingencies (Details) (USD \$)	9 Months Ended		
	Jun. 30, 2012	Sep. 30, 2011	May 06, 2009
Contingencies (Textual)			
Investment in MIT China Joint Venture	\$ 57,284	\$ 242,056	\$ 426,678
Equity loss from its investment	\$ 184,773		

MEDICAL INTERNATIONAL TECHNOLOGY INC
(Filer) CIK: 0001112372 (see all company filings)

IRS No.: **841509950** | State of Incorpor.: **CO** | Fiscal Year End: **0930**
Type: **10-Q** | Act: **34** | File No.: **000-31469** | Film No.: **121032116**
SIC: **3841** Surgical & Medical Instruments & Apparatus
Assistant Director 10

Business Address
1872 BEAULAC
STREET

Mailing Address
1872 BEAULAC
STREET

VILLE SAINT-

LAURENT A8 HR4 2E7
(514) 339-9355

VILLE SAINT-

LAURENT A8 HR4 2E7